Oncolytics Biotech Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Oncolytics Biotech Inc., a foreign private issuer based in Calgary, Alberta, Canada. The report covers the month of March 2004, with the specific filing date of March 30, 2004. The document serves as a notification to the Toronto Stock Exchange regarding a corporate action approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a stock option grant and does not contain a financial statement or performance summary.
Material Changes
The material event reported is the grant of stock options to purchase 50,000 common shares of the Corporation. The exercise price for these options is set at $6.90 per share, which corresponds to the closing price on the Toronto Stock Exchange on March 26, 2004. This grant is subject to regulatory approval and is made in accordance with the Corporation's stock option plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are discussed in this document, other than the standard condition that the option grant is subject to regulatory approval. The company indicated it will provide a detailed outline of grant activity in its subsequent monthly report.
Investor Verification Checklist
- Verify the regulatory approval status of the 50,000 stock options granted.
- Confirm the final exercise price of $6.90 per share in subsequent filings.
- Review the upcoming monthly report for a detailed outline of the grant activity.
- Check the company's stock option plan to ensure the grant complies with established limits and terms.